

Title: What do we know about the cost-effectiveness of HIV Pre-Exposure Prophylaxis, and is it affordable?

Authors:

Valentina Cambiano PhD¹, Alec Miners PhD², Andrew Phillips PhD¹

1. Research Department of Infection and Population Health, UCL, London, UK
2. Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK

Corresponding author:

Valentina Cambiano,

Research Department of Infection and Population Health, UCL, London, UK

Rowland Hill Street,

London NW3 2PF

0044 (0)207 794 0500 ext. 34570

v.cambiano@ucl.ac.uk

Wordcount: 3546

Journal: Current Opinion in HIV and AIDS

Abstract

Purpose of review

The World Health Organization recommends Pre-Exposure Prophylaxis (PrEP) in populations at substantial risk of HIV. Despite a number of randomized controlled trials demonstrating its efficacy, and several ongoing implementation projects, PrEP is currently only available in a few countries. Modelling studies can provide useful insights into the long term impact of introducing PrEP in different subgroups of the population. This review summarizes studies that either evaluated the cost-effectiveness or the cost of introducing PrEP, focusing on seven published in the last year.

Recent findings

These studies used a number of different types of models and investigated the introduction of PrEP in different settings. Among men having sex with men in North America, PrEP ranged from being cost-saving (while benefiting population health) to costing \$160,000/quality-adjusted life-year gained. Among heterosexual sero-different couples it varied from around \$5,000 to \$10,000/disability-adjusted life-year averted, when PrEP was used until six or twelve months after the HIV positive partner had initiated ART in, respectively, Uganda and South Africa.

Summary

Future cost-effectiveness studies of PrEP should consider the HIV incidence, the level of uptake, the effect of its introduction on alternative prevention approaches and the budget impact of rolling it out.

Keywords: cost-effectiveness, affordability, HIV prevention, modelling, pre-exposure prophylaxis

Introduction

Several guidelines and position statements have been issued recommending PrEP in people at high risk of contracting HIV to prevent HIV acquisition (See Table 1). The use of daily oral Truvada in HIV negative people has been approved in the US in 2012(10), while, in most countries, including Europe and Australia, PrEP is not available so far. Importantly, the World Health Organization (WHO) and the position released by the relevant medical associations in the UK highlighted the importance of estimating the cost-effectiveness of PrEP. WHO, in particular, reviewed the published literature on the cost-effectiveness of PrEP and took this into account when determining the strength of the evidence in the guidelines for key populations. WHO announced in July 2015 that updated guidance on PrEP will be released soon(11).

The strong evidence for the effectiveness of PrEP leaves countries and health providers facing the decision of whether to fund PrEP on top of the other HIV prevention programmes already in place and, if so, to decide which subgroups should receive it. Mathematical models provide a framework to combine all the information available on PrEP (uptake, efficacy, effectiveness, adherence, sexual behaviour while on PrEP, monitoring on PrEP and cost) to provide insights into the potential epidemiological impact, budget impact and cost-effectiveness of PrEP at a population level. A cost-effectiveness analysis compares the cost and outcomes of two or more different options and usually involves calculation of the cost of obtaining a gain in health (years of life, quality-adjusted life-years (QALY), deaths averted, infections averted, or disability-adjusted life-years (DALYs) averted). The advantage of calculating the cost per QALY gained (or, similarly, per DALY averted) is that this “incremental cost-effectiveness ratio” (ICER) can be compared across other interventions in any disease area. Budget impact analysis, on the other hand, consists of “assessing the financial consequences of the introduction of a new technology in a specific setting in the short-to-medium term” (21). These methods have only been relatively recently developed, but they are becoming more and more popular, as countries need to understand, not only whether new interventions

would be cost-effective, but as well whether they can afford the introduction of these new technologies.

In this paper, we review studies which evaluated the cost-effectiveness and/or affordability of PrEP-based HIV preventions, focussing on studies published in the past year. In particular, we aim to determine the settings and populations in which PrEP is likely to be cost-effective and affordable.

A number of literature reviews on the cost-effectiveness of PrEP have been performed: some specific to the US (22) and some more general (23). A previous literature review of cost-effectiveness studies in the US (all in MSM), concluded that there was substantial variation in the cost per QALY gained. The wide variation reflects the variation in the effectiveness assumed as well as the different type of models used, statics rather than dynamic. Gomez et al. (23) systematically reviewed the literature on cost-effectiveness of PrEP. The populations modelled were heterosexual couples, men who have sex with men (MSM) and people who inject drugs in generalised and concentrated epidemics from Southern Africa, Ukraine, USA, and Peru. They pointed out that offering PrEP to key populations appeared to be the most cost-effective strategy and that PrEP had the potential to be a cost-effective component of HIV prevention. The factors found to be most influential were costs, epidemic context, coverage of the prevention programme, the degree to which PrEP is targeted at population with high HIV incidence and adherence (affecting effectiveness). We now focus on the most recent studies to add to this literature.

Recent studies: search criteria and summary modelling considerations

In order to identify the most recent studies of interest the following terms (“cost” AND (“tenofovir” OR “pre-exposure prophylaxis” OR “chemoprophylaxis” OR “PrEP”) AND “HIV”) were used to search all databases in the Web of Science, starting from 1st July 2014. Eighty-three abstracts were retrieved and seven were identified as eligible as they contained either an evaluation of the cost-effectiveness of PrEP or an estimation of the cost of delivering PrEP (See Table 2).

In terms of the type of mathematical model used in these seven studies, one used a static decision model(24), three a dynamic deterministic compartmental model(25-27), one a dynamic stochastic microsimulation model(28), while two did not use mathematical models, either because they simply used the number needed to treat to estimate the average cost of the PrEP interventions to prevent one infection(29) or estimated the resources required to deliver PrEP and did not evaluate the cost-effectiveness of introducing it(30). The difference between static and dynamic models is that static models, typically used in health economics, do not take into account the fact that HIV is an infectious disease and therefore that by preventing directly one infection, more (secondary) infections are likely to be averted(31).

Recent studies: Model comparisons and main epidemiological assumptions

Summary details of the studies are provided in Table 2. Of the seven studies we identified, three were among MSM(24, 25, 29), three in heterosexual sero-different couples(26-28) and one in the general population attending primary health care clinics(30). Those conducted among MSM were all North American - from the US in general(24), Los Angeles(25) and Canada(29). The studies that focussed on sero-different couples were conducted from an African perspective - South Africa(28), Nigeria(26) and Uganda(27) and finally there was one based on attendees at primary health care clinics in South Africa(30). We will focus here primarily on the five published cost-effectiveness studies (not the abstract(25)).

All of the cost-effectiveness studies compared the introduction of PrEP to a scenario in which PrEP is not introduced (24-26, 28, 29), although some studies also considered the potential expansion of HIV testing and/or eligibility criteria for ART initiation (25, 27). A couple of them considered the introduction of PrEP in combination either with condom promotion and ART to all those diagnosed with HIV(26) or with an increase in ART coverage in couples at high risk(27).

Only two studies provided the HIV incidence in the comparator scenario in which PrEP was not introduced, being 2.7 per 100 person-years(28) and a median of 5 per 100 person-years (26). The effectiveness of PrEP against HIV was assumed to be 44% by Chen & Dowdy and Ouellet et al. (24, 29), based on the IPrEx study conducted among MSM in several countries including the US (1) (92% in an alternative scenario in Chen&Dowdy), 70% (range: 44-90%) by Mitchell et al.(26), 90% by Jewell et al.(28) and 92% (range: 77%-98%) by Ying et al.(27), all based on the Partners PrEP study (3).

The duration of the PrEP intervention was one year in the studies conducted among MSM in North America (24, 29), for a variable length of time, from enrolment to respectively six months and one year since ART initiation of the HIV positive partner in sero-different couples in Uganda(27) and South Africa(28), while until HIV acquisition or ART initiation of the positive partner for the HIV negative partners in the sero-different couples in Nigeria (26).

Only one study considered the potential impact of a decrease in condom use in people receiving PrEP(24) and none of them considered other possible negative consequences of PrEP: such as the development of resistance or toxicities due to PrEP, however there is no evidence from the RCTs for these to be major issues.

Recent studies: Cost-effectiveness parameters

The cost assumed for one year of PrEP varies substantially across studies, mainly driven by the setting. In South Africa and Nigeria this was assumed to be around \$250 per year (26, 28), in Uganda this was estimated to be respectively \$408 and \$92 in the study and government settings (27), while in North America it was assumed around \$10,000 per year (range \$5,000 to \$15,000) (including the cost of documenting HIV negative status, renal function tests prior to PrEP initiation, quarterly clinic

visits, HIV testing, bi-annual screening for STI and bi-annual renal function testing) by Chen et al.(24) and \$11,760 (Canadian \$12,000) by Ouellet et al.(29).

Three of the seven studies considered a societal perspective (this means that the cost and benefit incurred by the society as a whole are taken into account: direct medical and non-medical costs (e.g. patient transportation to attend the clinic), indirect costs (e.g. time lost from work) and intangible costs (e.g. pain and suffering))(24, 25, 29), one study took a health care system perspective(28), two the provider perspective(26, 27). The studies conducted among MSM in North America considered a lifetime horizon(24, 29), while the studies among sero-different couples in Nigeria and South Africa used a time horizon of 20 years(26, 28) and the one in Uganda 10 years (27). All the cost-effectiveness studies discounted the costs and effects using an annual discount rate of 3% per year(24, 27-29), with the exception of Mitchell et al. (26) that used an annual discount rate of 10% per year, due to the high predilection for present in Nigeria.

All cost-effectiveness studies used as measure of health benefit used either the DALYs averted (26-28) or the QALYs gained(24, 29) and some in addition considered infections averted(26, 27). The disability weights for HIV positive people used were taken either from a meta-analysis (32) conducted few year ago (24, 29), or from the Global Burden of Disease study performed in 2004(33) or in 2010(26, 27, 34).

Finally, regarding the cost-effectiveness threshold used, only the studies set in Africa (26, 27) reported this explicitly. They used a cost-effectiveness threshold of three times gross domestic product (GDP) per capita to be cost-effective and one time GDP per capita to be considered very cost-effective(35), as was used in previous WHO material, which is considered unlikely for low and middle income countries, given in the UK it has been estimated to be around 0.4 of the GDP per capita(36).

Cost-effectiveness of Pre-Exposure Prophylaxis in MSM in North America

Chen & Dowdy(24) estimated the introduction of PrEP for one year (44% efficacious) among HIV negative MSM living in the US will cost \$160,000/QALY gained over a lifetime horizon (95% uncertainty range: cost saving to \$740,000) in the base case. However they considered alternative scenarios which made PrEP cost-saving (when an HIV prevalence of 0.35 and high adherence to PrEP - such that the PrEP efficacy was 92% - were assumed) and on the other hand scenarios which increased the ICER up as far as \$840/QALY gained (in the case of 100% condom use).

Most recently, Ouellet et al.(29) evaluated the cost-effectiveness of one year of 'on demand' PrEP (as used in the Ipergay trial(2)), among non-injection drug-using MSM in Canada. They used the number -needed-to-treat; 51.78, estimated from the iPrEx trial), to calculate the total number of non-injection drug-using MSM needed to be on PrEP to prevent one HIV infection and estimated the lifetime cost of living with HIV, assuming infections occur at age 30, with a life-expectancy of 35.2 years. They found that at 0% and 3% discount rates the PrEP intervention was cost-saving, while when using a 5% discount rate the ICER varied from Canadian \$47,338/QALY gained, in the most expensive scenario (1 Canadian \$ = 0.98 US\$), to Canadian \$60,223 in the least expensive case.

The three studies(24, 25, 29) present significant differences in the base case ICER: from cost-saving(29) to \$160,000/QALY gained(24). However, given Chen & Dowdy used a static model, which does not take into account secondary infections averted, we would expect this study to obtain less favourable ICERs. In addition, even this study found PrEP to be a cost-saving option in situations characterized by high adherence (corresponding to a PrEP efficacy of 92%) and being used in a high HIV prevalence population (0.35). Importantly, studies recently published on the cost-effectiveness of PrEP in high income countries have started taking a societal perspective, allowing them to take into account the cost incurred by the entire society and therefore some of the advantages of keeping people free from HIV. Unfortunately, none of these studies conducted a budget impact analysis necessary to determine its affordability.

Cost-effectiveness of Pre-Exposure Prophylaxis among sero-different couples in Africa

Before this last year, only one study had evaluated the cost-effectiveness of PrEP among sero-different couples (37). They had found that PrEP could be highly cost-effective in this population group and even cost-saving. They estimated that if the annual cost of PrEP is less than 40% the annual cost of ART and if PrEP is more than 70% effective then offering PrEP to the HIV-negative partner could be at least as cost-effective as initiating ART earlier in the positive one.

Recently, three studies evaluated the cost-effectiveness of PrEP among sero-different couples in Africa (26-28).

Jewell et al.(28) envisaged an intervention where PrEP (90% efficacious against HIV) would be used by the HIV uninfected partner of sero-different couples living in South Africa before the HIV positive partner initiates ART and for one year thereafter. They found that this intervention with (33% efficacy against HSV-2) or without protection against HSV-2, would be cost-effective , with ICERs (over 20 year time horizon) of respectively \$9,757 and \$10,383/DALY averted (South Africa GDP in 2012 \$7,314). In the sensitivity analyses they found that if all couples were sero-different not only for HIV but for HSV-2 as well, the ICER could be further reduced to \$1,445/DALY averted.

Mitchell et al. (26) compared the cost-effectiveness of condom promotion, treatment as prevention, PrEP and their combination against a baseline scenario characterized by eligibility criteria for ART initiation of $CD4 \leq 350$ cells/mm³ for sero-different couples in Nigeria. They found that the most cost-effective strategy was condom promotion with an ICER of \$1206/DALY averted, followed by condom promotion in combination with treatment as

prevention (ICER: \$1,607/DALY averted), followed by the addition of PrEP (ICER: \$7870/DALY averted). The order of incrementally cost-effective interventions remained the same when varying the discount rate (range: 3%-15%), initial PrEP coverage (range: 40-80%) or initial condom promotion coverage (range: 40-80%).

However, with a discount rate of 3% (more commonly used, rather than 10%) and with lower initial condom promotion coverage the ICERs are reduced. When considering a time-frame of 10 years (rather than 20), the most cost-effective intervention became Tasp, followed by condom promotion +TasP, while when considering a lifetime frame the ICERs are improved. This is due to the fact that TasP will have a more immediate effect in averting DALYs by improving survival in people at low CD4, while the introduction of PrEP has an effect on DALYs later in time, by averting HIV

infections. Ying et al. (27) estimated the cost-effectiveness of a short-term use of PrEP in HIV negative partners of high-risk sero-different couples in Uganda. The PrEP intervention is similar to the one described by Jewell et al.(28), but until six rather than twelve months after the HIV positive partner's ART initiation and in combination with an increase in ART coverage (assumed currently 40% in Uganda) among the HIV positive partners of high-risk sero-different couples. They reported

that this intervention would be very cost-effective in terms of HIV infections averted, but not cost-effective in terms of cost per DALY averted (\$5,334/DALY). They found that clinical capacity played an important role with ICER varying from \$4,648/DALY averted with high clinical capacity (1500 couples annually) to \$18,151/DALY averted with low clinical capacity (200 couples annually). When varying other relevant assumptions (ART cost at \$100/person-year, rather than \$269/person-year, discount rate of 0%, rather than 3% and drop-out from ART and PrEP programme of 10%, rather than 3%) the PrEP intervention remains cost-effective for averting DALYs but not very cost-effective, while it remains the most cost-effective strategy for averting HIV infections across all ranges of assumptions.

These three studies considered a relatively similar PrEP intervention in sero-different couples, all using dynamic models and with a relatively short time frame, either ten or twenty years. The cost-effectiveness of the PrEP intervention alone, assessed by Mitchell et al. and Jewell et al., varied from being dominated (meaning that the intervention costs more and is no more effective than the comparator) in Nigeria to a cost of around \$10,000/DALY averted in South Africa, where it is cost-effective. When considering the combination of the PrEP intervention with condom promotion and TasP in Nigeria, the addition of PrEP was cost-effective, only after condom promotion and condom promotion in combination with Tasp at an ICER of \$7,870/DALY averted, while in Uganda a programme of PrEP and ART in high risk couples cost \$5,334/DALY averted, which means PrEP is unlikely to be cost effective in these circumstances. The ICER threshold for an intervention to be considered cost effective is the subject of much debate, and the often used threshold of one or three times the per capita GDP is widely considered to be too high (38).

The difficulty in comparing these estimates comes from the fact the possible scenarios included differs and so do the countries where these studies are set. In particular there are substantial differences in terms of HIV incidence assumed in these couples (2.7 per 100 person-years in the

study set in South Africa(28) to 5 per 100 person-years in the study set in Nigeria(26)), ART eligibility and coverage in the reference scenario (CD4<350 cells/mm³ in the studies set in South Africa and Nigeria, with assumed ART coverage of 100% in Nigeria and of CD4<500 cells/mm³ with 40% ART coverage in the study in Uganda) and the cost-effectiveness threshold, which is based on the GDP per capita (\$11,440 for South Africa, \$2,742 for Nigeria, \$1,681 for Uganda). When considering the parameters varied in sensitivity analyses in these three studies, they do not overlap. The parameters that were significantly affecting the results are the proportion of couples sero-different for both HIV and HSV-2 in Jewell et al.(28), the discount rate and the time frame in Mitchell et al. (26) and the clinical capacity in Ying et al.(27).

Recent studies: Costing of delivering Pre-Exposure Prophylaxis

Only two studies presented a costing for delivery of a PrEP programme. Homan et al. estimated the additional cost of using a quality improvement approach to integrate the offer of TDF gel (topical PrEP) in primary healthcare clinic and strengthen family planning services in KwaZulu-Natal (South Africa)(30). They estimated the resources necessary to introduce the quality improvement approach are minimal (\$18,660) compared to the cost for gel delivery (\$89,500). While Ying et al. conducted a micro-costing study within a PrEP implementation project and estimated the cost in the research setting and in government setting to be respectively \$408 and \$92 per couple per year.

Conclusions

There has been a move for studies of cost-effectiveness of PrEP to focus on populations at high risk of contracting HIV. All the studies published in the last year all focused on some of the key populations: MSM in high income countries and sero-different couples in African countries. In addition, those among sero-different couples envisaged a short-term PrEP intervention but in a period of time in which the HIV negative person is considered at high risk of contracting HIV. Clearly offering PrEP to subgroups of the population and for periods of time where the person is at

particularly high risk helps to improve the cost-effectiveness of PrEP. However, identification and successful targeting of these subgroups at higher risk of contracting HIV is not always straightforward.

In addition, some studies (23) concluded that the maximum benefit from PrEP introduction could be realised if introduced in combination with HIV prevention programmes.

Compared to the previous cost-effectiveness studies of PrEP reviewed, some of the recent studies developed further investigation of the role of other prevention interventions (such as expansion of HIV testing and ART) in combination or as alternatives to PrEP, some(26) found that PrEP would not be the most cost-effective, but all found it to be cost-effective as an addition (when considering a time frame of 20 years). Unfortunately, most studies do not report the HIV incidence which is clearly a key parameter in determining the cost-effectiveness of PrEP introduction (with PrEP more likely to be cost effective if incidence is high) and that could help explain the difference in results. The appropriate cost- effectiveness threshold to be using in a given setting remains a key issue that is not fully resolved.

The other crucial element to determine the cost-effectiveness of any intervention is clearly its cost and the cost of its delivery. Ongoing implementation projects are paramount to inform countries on how to deliver PrEP (who, where, how), how much it will cost and what level of capacity is necessary to make it cost-effective. Most of the studies presented cost-effectiveness analyses, but not budget impact analyses, with the exception of Ying et al. which estimated, by conducting a micro costing study, the expenditure within a PrEP implementation project and extrapolated the cost if the programme was to be run by the government. Budget impact analyses are extremely important for health providers when deciding whether to introduce PrEP and are increasingly requested by reimbursement authorities (39). The cost-effectiveness of an intervention does not in itself imply affordability. This means that even if an intervention is found cost-effective and if the country typically uses this criterion to decide on how to distribute the resources on health, this does not

mean it will make the policy decision to pay to introduce them. The use of Sofosbuvir for treatment of hepatitis C is an example of this in the UK (40)).

Key points:

- Based on studies in the past year, among MSM in North America the estimated cost-effectiveness of PrEP ranges from cost-saving to \$160,000/QALY gained reflecting differences in efficacy (86% vs 44%) and type of model used.
- Among heterosexual sero-different couples the introduction of PrEP is cost-effective in South Africa when considering a relatively short term used (until one year after the HIV positive partner has initiated ART), but not in Uganda, unless we consider the cost per infection averted. In Nigeria, the introduction of PrEP was not found to be cost-effective on its own, but was in combination with condom promotion and offer of ART at diagnosis, after these have been implemented.
- To help decisions of public funding of PrEP, given the current economic situation, efforts should be made to evaluate not only the cost-effectiveness but also the budget impact of PrEP.
- All recent cost-effectiveness studies published as manuscripts find circumstances (e.g. higher prevalence, as a proxy of HIV incidence, short term use during a period of high risk, higher adherence and therefore effectiveness, in combination with ART at diagnosis and condom promotion, or with high clinical capacity) in which PrEP, in principle, could be cost-effective, if not cost-saving.
- It is now time to consider in more detail the PrEP implementation factors, including the uptake, the actual way of identifying subgroups of the population at high risk of contracting HIV, the length of the PrEP intervention, related to the actual risk, and clearly the actual cost of delivering PrEP.

Tables

Table 1. Guidelines and Position statements on Pre-Exposure Prophylaxis Use and how they addressed issues of costs, cost-effectiveness, and affordability

Year	Setting	Body	Title	Issues of costs, cost-effectiveness and affordability	Citation
Jan 2011	US	CDC	Interim Guidance: Pre-exposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men	Not mentioned. In the Editorial note it is highlighted the importance of ensuring "patients understand the financial implications of starting PrEP".	(41)
Jan 2012	UK	BHIVA/ BASHH	The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK	Cost is mentioned as a concern if PrEP had to be widespread used in the UK. In addition, they stated that "It is imperative to gather evidence for the value of PrEP in the UK".	(42)
Jun 2012	South Africa	Southern African Clinicians Society	Southern African guidelines for the safe use of pre-exposure prophylaxis in men who have sex with men who are at risk for HIV infection	Not mentioned.	(43)
Jul 2012	World-wide	WHO	Guidance on Pre-Exposure oral Prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: Recommendations for use in the context of demonstration projects	The authors highlighted that despite resource costs being collected during the trials, there is poor understanding of their applicability outside this context. They reviewed the cost-effectiveness studies published at the time and recommended PrEP, taking into account the estimated potential cost-effectiveness of PrEP. Out of pocket costs are mentioned one of the factors influencing PrEP acceptability. They underlined the need for demonstration projects and specified that countries will need to evaluate the best allocation of their available resources for HIV prevention, taking in account of the potential role of PrEP.	(44)
Aug 2012	US	CDC	Interim Guidance for Clinicians Considering the Use of Pre-exposure Prophylaxis for the Prevention of HIV Infection in Heterosexually Active Adults	Not mentioned.	(45)

May 2014	US	US Public Health Service	Pre-Exposure Prophylaxis for the prevention of HIV infection in the United States - 2014 A clinical practice guidelines	Low out-of-pocket costs are mentioned as one of the most important factor for being adherent to medications by chronic diseases patients.	(46)
Jul 2014	World-wide	WHO	Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations	Costs and financial implications have been taken into account when establishing the strength of the recommendations, included in this guidelines. Regarding PrEP, they concluded that there was variability regarding its cost-effectiveness, highly dependent on the drug price.	(47)
Apr 2015	Europe	ECDC	Evidence suggests that the use of pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM) is an effective HIV prevention tool for Europe.	Not mentioned	(48)

BHIVA: British Association for Sexual Health and HIV; CDC: Centers for Disease Control and Prevention; ECDC: European Centre for Disease Control and Prevention ; UK: United Kingdom; US: United States; WHO: World Health Organization;

Table 2. Recent studies of the cost–effectiveness of Pre-Exposure HIV Prophylaxis^

	Chen et al.(24)	Drabo et al.(25)	Ouellet et al.(29)	Jewell et al.(28)	Mitchell et al.(26)	Ying et al. (27)
Type of publication	Peer-reviewed paper	Conference abstract	Peer-reviewed paper	Peer-reviewed paper	Peer-reviewed paper	Peer-reviewed paper
Setting and population	MSM in the US	MSM in LA County (US)	Non-injection drug-using MSM in Canada	Heterosexual sero-different couples in KwaZulu-Natal (South Africa)	Heterosexual sero-different couples in Nigeria	High risk* heterosexual sero-different couples in Uganda (the Partner Demonstration Project)
Model type	Static decision	Dynamic deterministic compartmental	No mathematical model used. NNT used to estimate the ICER	Dynamic stochastic microsimulation	Dynamic deterministic compartmental	Dynamic deterministic compartmental
Duration and type of PrEP intervention	1 year of daily PrEP	NA	1 year of on demand PrEP	Daily PrEP used by the HIV uninfected partner before the HIV positive partner initiates ART and for one year thereafter	PrEP used by 60% of HIV uninfected partners, until the first event among: ART initiation of the HIV positive partner, HIV acquisition or death.	PrEP used by 80% of HIV uninfected partners before the HIV positive partner initiates ART and for 6 months thereafter (6% drop out rate) and ART in 40% of those with CD4≤500 cells/mm ³ , but 80% of all HIV positive partners in high-risk sero-discordant couples.
Comparator scenario	No PrEP (ART initiation NA; 36% of HIV positive partners on ART)	No PrEP (ART initiation at CD4≤500 cells/mm ³)	No PrEP	No PrEP (ART initiation at CD4≤350 cells/mm ³)	No PrEP (ART initiation at CD4≤350 cells/mm ³)	No PrEP (ART in 60% of those with CD4≤200 cells/mm ³ , in 50% of those with

						CD4 200-350 cells/mm ³ and 10% of those with CD4 350-500 cells/mm ³ ; overall 40%)
HIV incidence or prevalence	0.53% baseline risk of HIV acquisition per sex act (0.19 HIV prevalence)	NA	NA	HIV incidence of 2.7 per 100 person-years	HIV incidence between 2 and 9 per 100 person-years (median 5 per 100 person-year)	NA
PrEP effectiveness	44% based on IPrEx study (92% in alternative)	NA	44% based on IPrEx study	90% based on Partners PrEP study	70% (44%-90%) based on Partners PrEP study	92% (77%-98%) based on Partners PrEP study
Cost of PrEP (US \$)	\$10,000 (range: \$5,000 - \$15,000) per year	NA	\$11,760 (Canadian \$12,000) per year	\$250 per year	\$118 (range: \$82.6-\$153.4) for PrEP initiation, \$233 (range: \$163.1-\$302.9) per year.	\$408 in the study setting, \$92 in the government setting.
Perspective of the analysis	Societal	Societal	Societal	Health care	Provider	Provider
Time horizon	Lifetime	NA	Lifetime	20 years	20 years	10 years
Annual discount rate	3%	NA	0%, 3% and 5%	3%	10% (3% and 15% in sensitivity analyses)	3% (0% and 10% in sensitivity analyses)
Outcome measure	ICER (Cost per QALY gained)	ICER (Cost per QALY gained)	ICER (Cost per QALY gained)	ICER (Cost per DALY averted)	ICER (Cost per DALY averted and per infection averted)	ICER (Cost per DALY averted and per infection averted)
Source for disability weights/utilities	Meta-analysis (32); Global Burden Disease Study 2004 (33)	NA	Meta-analysis (32)	Global Burden of Disease study 2010 (34) and the Iran Burden of Disease and Injury Study, 2003 (49)	Global Burden of Disease study 2010 (34)	Global Burden of Disease study 2010 (34)

CE threshold	NA	NA	NA	Cost-effective if ICER <3 times South Africa GDP per capita	Cost-effective if ICER <3 times Nigeria GDP per capita (\$8,226) per DALY averted; highly cost-effective if ICER <1 time Nigeria GDP (\$2,742).	Cost-effective if ICER <3 times 2012 Uganda GDP per capita (\$5,043). Very cost-effective if ICER <1 time 2012 Uganda GDP per capita (\$1,681).
ICER of PrEP intervention in the base care (US \$ if not specified)	\$160,000/QALY gained (95% UR: cost saving -\$740,000);	\$26,000/QALY gained;	At 0% and 3% discount rate: cost-saving; At 5% discount rate: range from \$46,000/QALY gained in the most expensive scenario \$59,000 in the least expensive.	\$9,757/DALY averted, assuming 33% efficacy of PrEP against HSV-2 and \$10,383/DALY averted, assuming no efficacy against HSV-2.	Condom promotion was the most cost-effective strategy (\$1206/DALY averted)-effective is condom promotion in combination with ART at diagnosis (\$1,607/DALY averted) and only at this point the addition of PrEP would be cost-effective (\$7,870/DALY averted).	A programme of PrEP and ART: \$1,340 per infection averted and \$5,334 per DALY averted; A programme of ART alone (in 90% of those with CD4≤500 cells/mm ³): \$1,452 per infection averted and 1,075 per DALY averted.
ICER (expressed in US \$) in sensitivity analyses	Higher level of HIV prevalence and high adherence to PrEP: cost-saving; 100% condom use: \$840/QALY gained;	NA	Range presented in the base case.	If all couples sero-different for HIV both HIV and HSV-2: \$1,445/DALY averted	With 15% discount rates cost-effectiveness is reduced. With 3% discount rate the order of cost-effectiveness among interventions is the	Clinical capacity: high (1500 couples annually) ICER of \$4,648/DALY averted; low (200 couples): \$18,151/DALY averted. With ART cost at \$100/person-year,

					<p>same but the ICERs are lower.</p> <p>With a time-frame of 10 (rather than 20) years, TasP is the most cost-effective intervention, followed by condom promotion +TasP.</p> <p>The initial PrEP coverage (40 and 80% rather than 60%) had a small impact on DALYs averted, although had an impact on total costs. Lower initial condom promotion coverage (40 or 60% rather than 80%) reduced to some extent both costs and DALYs averted, and cost per DALY, but the order remained the same.</p>	<p>0% annual discounting, 10% drop-out from ART and PrEP programme is cost-effective for averted DALY but not very cost-effective. PrEP remains the most cost-effective strategy for averting HIV infections across all ranges of assumptions.</p>
--	--	--	--	--	--	--

Costs are in US dollars if indicated as \$.

ART: antiretroviral therapy; CE: cost-effectiveness; DALY: disability-adjusted life-year; ICER: incremental cost-effectiveness ratio; LA: Los Angeles; MSM: men having sex with men; NA: not available; NNT: number needed to treat; PrEP: Pre-Exposure Prophylaxis; QALY: quality-adjusted life-year; STI: sexually transmitted infections; UR: uncertainty range; US: United States;^The costing study by Homan et al. is not included in this table, as it did not evaluate the PrEP cost-effectiveness.

*defined as couples where the HIV negative partner is aged <25 years and belongs to the top 15th percentile in the number of casual sex partners;

Acknowledgments: We would like to acknowledge KohJun Ong, who contributed in reviewing some of the studies. VC has received honorarium from Merck Sharp & Dohmed Limited, outside the submitted work. For the remaining authors none were declared.

References

I will annotate the following:

6. Chen A, Dowdy DW. Clinical Effectiveness and Cost-Effectiveness of HIV Pre-Exposure Prophylaxis in Men Who Have Sex with Men: Risk Calculators for Real-World Decision-Making. *Plos One*. 2014;9(10).

** Simple static decision analytic model of HIV negative MSM living in the US with a cost-effectiveness calculator available on line to allow stakeholders, by inputting parameters specific to the area of interest (HIV prevalence, ART coverage, condom use, etc.) to evaluate area specific PrEP cost-effectiveness and a personalized risk calculator to help clinicians discuss PrEP with the person at risk of HIV acquisition.

7. Drabo EF, Hay JW, Vardavas R, Wagner Z, Sood N. ROLLING OUT ORAL PRE-EXPOSURE PROPHYLAXIS (PREP) IS A COST-EFFECTIVE HIV PREVENTION STRATEGY AMONG THE LOS ANGELES COUNTY (LAC) MEN WHO HAVE SEX WITH MEN (MSM). *Value in Health*. 2015;18(3):A237-A.

*Interesting conference abstract, using a deterministic compartmental model, to evaluate the cost-effectiveness of PrEP and increase in HIV testing and expansion of eligibility criteria for ART initiation among MSM aged 15-65 in Los Angeles County

8. Mitchell KM, Lepine A, Terris-Prestholt F, Alhassan E, Idoko J, Vickerman P. Mathematical Modelling to Estimate the Impact and Cost-effectiveness of TasP, PrEP and Condom Promotion for Serodiscordant Couples in Nigeria. *Aids Research and Human Retroviruses*. 2014;30:A73-A.

**Stimulating paper showing that among sero-different couples in Nigeria PrEP is cost-effective, only in combination with ART at diagnosis and condom promotion and once ART coverage and eligibility criteria have been expanded and condom promoted.

9. Ying R, Sharma M, Heffron R, Celum CL, Baeten JM, Katabira E, et al. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda. *J Int Aids Soc.* 2015;18:21-9.

**Important study estimating the cost of delivering ART and PrEP within a PrEP implementation project (by micro-costing) and estimating its potential reduction if it was to be run by the government. In addition they evaluated the cost-effectiveness of introducing PrEP, in combination with an increase in ART coverage in sero-different couples at high risk, identified to be at high risk.

10. Jewell BL, Cremin I, Pickles M, Celum C, Baeten JM, Delany-Moretlwe S, et al. Estimating the Cost-Effectiveness of Pre-Exposure Prophylaxis to Reduce HIV-1 and HSV-2 Incidence in HIV-Serodiscordant Couples in South Africa. *Plos One.* 2015;10(1).

**Fascinating study showing that the use of PrEP in the HIV uninfected partner of sero-different couples before the HIV positive partner initiates ART and for one year afterwards is cost-effective and that the contribution of a partial protection against HSV-2 is minimal, mainly driven by the fact that the majority of couples is not sero-different for HSV-2.

11. Oullet E, Durand M, Guertin JR, LeLorier J, Tremblay CL. Cost effectiveness of 'on demand' HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in Canada. *Canadian Journal of Infectious Diseases & Medical Microbiology.* 2015;26(1):23-9.

**Attractive simple study using the number needed to treat to estimate the cost of PrEP intervention to avert one HIV infection. They used a societal perspective and focused on carefully costing the intervention based on the IPERGAY study.

12. Homan R, Dlamini S, Mansoor L, Valodia I, Sortijas S, Watson S, et al. Introducing Microbicides: Estimated Cost of QI Approach and Tenofovir Gel Delivery with Family Planning Services in the CAPRISA 008 Trial. *Aids Research and Human Retroviruses*. 2014;30:A284-A.

*Interesting abstract estimating the cost of a quality improvement approach to integrate the delivery of TDF gel in primary healthcare setting and strengthen family planning services.

Reference List

1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. *N Engl J Med*. 2010;363(27):2587-99.
2. Molina JMC, C.; Charreau, I.; Meyer, L.; Spire, B.; Pialoux, G.; et al., editor On Demand PrEP With Oral TDF-FTC in MSM: Results of the ANRS Ipergay Trial. Conference on Retroviruses and Opportunistic Infections; 2015; Seattle.
3. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. *N Engl J Med*. 2012;367(5):399-410.
4. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. *N Engl J Med*. 2012;367(5):423-34.
5. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*. 2013;381(9883):2083-90.
6. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. *Science*. 2010;329(5996):1168-74.
7. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. *N Engl J Med*. 2012;367(5):411-22.
8. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodini N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. *N Engl J Med*. 2015;372(6):509-18.
9. Rees HD-M, S.; Baron, D.; Lombard, C.; Gray, G.; Myer, L.; Panchia, R.; Schwartz, J.; Doncel, G.;, editor FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women. Conference on Retroviruses and Opportunistic Infections; 2015 26/02/2015; Seattle.
10. FDA approves first drug for reducing the risk of sexually acquired HIV infection [press release]. 16/07/2012 2012.
11. UNAIDS WaA. Oral pre-exposure prophylaxis: putting a new choice in context Geneva: UNAIDS; 2015 [updated 07/201515/09/2015]. Available from: <http://www.who.int/hiv/pub/prep/who-unaid-prep-2015.pdf?ua=1>.
12. Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. *Lancet Infect Dis*. 2014;14(11):1055-64.
13. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. *Lancet Infect Dis*. 2014;14(9):820-9.
14. Martin MM, P.; Curlin, M.; Vanichseni, S.; Suntharasamai, P.; Sangkum, U.; Choopanya, K.; Leethochawalit, M.; Chiamwongpaet, S.; Kittimunkong, S., editor Preliminary Follow-up of Injecting Drug Users Receiving Preexposure Prophylaxis. Conference on Retroviruses and Opportunistic Infections; 2015 26/02/2015; Seattle2015.
15. Baeten JH, R.; Kidoguchi, L.; Celum, C.; Mugo, N.; Bukusi, E.; Katabira, E.; Asimwe, S.; Haberer, J.; Donnell, D.;, editor Near Elimination of HIV Transmission in a Demonstration Project of PrEP and ART. Conference on Retroviruses and Opportunistic Infections; 2015 22/02/2015; Seattle.
16. Chirwa LT, A.; Williams, T.; Henderson, F.; Kasonde, M.; Mutanhaurwa, R.; Matlhaba, O.; Hageman, K.; Casillas, P.; Samandari, T.;, editor Enrollment into open-label phase of TDF2 PrEP Study, Botswana, 2013. International AIDS Conference; 2014; Melbourne, Australia.

17. Mugwanya KK, Donnell D, Celum C, Thomas KK, Ndase P, Mugo N, et al. Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. *Lancet Infect Dis.* 2013;13(12):1021-8.
18. McCormack SD, D. on behalf of the PROUD Study, editor Pragmatic open-label randomised trial of preexposure prophylaxis: the PROUD study. Conference on Retroviruses and Opportunistic Infections; 2015 26/02/2015; Seattle, Washington2015.
19. Cohen SE, Vittinghoff E, Bacon O, Doblecki-Lewis S, Postle BS, Feaster DJ, et al. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. *J Acquir Immune Defic Syndr.* 2015;68(4):439-48.
20. Prevention AGAfH. Ongoing and Planned PrEP Demonstration and Implementation Studies 2015 [cited 2015 22/07/2015]. Available from: http://www.avac.org/sites/default/files/resource-files/PrEP_Trials_Demo_Projects_June2015.pdf.
21. Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. *Pharmacoeconomics.* 2001;19(6):609-21.
22. Hellinger FJ. Assessing the cost effectiveness of pre-exposure prophylaxis for HIV prevention in the US. *Pharmacoeconomics.* 2013;31(12):1091-104.
23. Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. *PLoS Med.* 2013;10(3):e1001401.
24. Chen A, Dowdy DW. Clinical Effectiveness and Cost-Effectiveness of HIV Pre-Exposure Prophylaxis in Men Who Have Sex with Men: Risk Calculators for Real-World Decision-Making. *Plos One.* 2014;9(10).
25. Drabo EF, Hay JW, Vardavas R, Wagner Z, Sood N. ROLLING OUT ORAL PRE-EXPOSURE PROPHYLAXIS (PREP) IS A COST-EFFECTIVE HIV PREVENTION STRATEGY AMONG THE LOS ANGELES COUNTY (LAC) MEN WHO HAVE SEX WITH MEN (MSM). *Value in Health.* 2015;18(3):A237-A.
26. Mitchell KML, A.; Terris-Prestholt, F.; Torpey, K.; Khamofu, H.; Folayan, M.; Musa, J.; Anenih, J.; Sagay, A.; Alhassan, E.; Idoko, J.; Vickerman, P.;. Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria. *Aids Research and Human Retroviruses.* 2015;29(15):10.
27. Ying R, Sharma M, Heffron R, Celum CL, Baeten JM, Katabira E, et al. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda. *J Int Aids Soc.* 2015;18:21-9.
28. Jewell BL, Cremin I, Pickles M, Celum C, Baeten JM, Delany-Moretlwe S, et al. Estimating the Cost-Effectiveness of Pre-Exposure Prophylaxis to Reduce HIV-1 and HSV-2 Incidence in HIV-Serodiscordant Couples in South Africa. *Plos One.* 2015;10(1).
29. Ouellet E, Durand M, Guertin JR, LeLorier J, Tremblay CL. Cost effectiveness of 'on demand' HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in Canada. *Canadian Journal of Infectious Diseases & Medical Microbiology.* 2015;26(1):23-9.
30. Homan R, Dlamini S, Mansoor L, Valodia I, Sortijas S, Watson S, et al. Introducing Microbicides: Estimated Cost of QI Approach and Tenofovir Gel Delivery with Family Planning Services in the CAPRISA 008 Trial. *Aids Research and Human Retroviruses.* 2014;30:A284-A.
31. Lugner AK, Mylius SD, Wallinga J. Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. *Health Econ.* 2010;19(5):518-31.
32. Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. *Med Decis Making.* 2002;22(6):475-81.
33. Organization WH. The Global Burden of Disease 2004 update: Disability Weights for Diseases and Conditions. 2004.
34. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet.* 2012;380(9859):2197-223.

35. Organization WH. Cost effectiveness and strategic planning (WHO-CHOICE) 2015 [28/07/2015]. Available from: http://www.who.int/choice/costs/CER_thresholds/en/.
36. Claxton KM, S.; Soares, M.; Rice, N.; Spackman, E.; Hinde, S.; Devlin, N.; Smith, P.C.; Sculpher, M. Methods for the Estimation of the NICE Cost Effectiveness Threshold. The University of York, 2013 2013. Report No.
37. Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, Cremin I, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. *PLoS Med.* 2011;8(11):e1001123.
38. Woods BR, P; Sculpher, M.; Claxton, K. Country-Level CostEffectiveness Thresholds: Initial Estimates and the Need for Further Research. 2015.
39. Sullivan SD, Mauskopf JA, Augustovski F, Caro JJ, Lee KM, Minchin M, et al. Budget Impact Analysis Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. *Value in Health.* 2014;17(1):5-14.
40. Boseley S. Hepatitis C drug delayed by NHS due to high cost: *Guardian*; 2015 [updated 20/01/201528/07/2015]. Available from: <http://www.theguardian.com/society/2015/jan/16/sofosbuvir-hepatitis-c-drug-nhs>.
41. Prevention CfDCa. Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex with Men. 2011 28/01/2011. Report No.: Contract No.: 03.
42. McCormack S, Fidler S, Fisher M, British HIVA, British Association for Sexual H, Hiv. The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UK. *Int J STD AIDS.* 2012;23(1):1-4.
43. Committee SAHCSC. Southern African guidelines for the safe use of pre-exposure prophylaxis in men who have sex with men who are at risk for HIV infection. *Southern African Journal of HIV Medicine.* 2012;13(2):15.
44. Organization WH. Guidance on Pre-Exposure oral Prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: Recommendations for use in the context of demonstration projects Geneva, Switzerland.: World Health Organization, 2012.
45. Prevention CfDCa. Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis for the Prevention of HIV Infection in Heterosexually Active Adults. Center for Disease Control and Prevention, 2012 10/08/2012. Report No.: Contract No.: 31.
46. Service USPH. Pre-exposure prophylaxis for the prevention of HIV infection in the United States - 2014 A clinical practice guideline. 2014 14/05/2014. Report No.
47. Organization WH. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Layout L'IV Com Sàrl, Villars-sous-Yens, Switzerland: 2014.
48. Pre-exposure prophylaxis to prevent HIV among MSM in Europe [press release]. 2015.
49. Naghavi M, Abolhassani F, Pourmalek F, Lakeh M, Jafari N, Vaseghi S, et al. The burden of disease and injury in Iran 2003. *Popul Health Metr.* 2009;7:9.